Actively Recruiting
The Overall Survival of Patients With Unresectable HCC in Real-life
Led by Humanity & Health Medical Group Limited · Updated on 2025-03-24
5000
Participants Needed
3
Research Sites
389 weeks
Total Duration
On this page
Sponsors
H
Humanity & Health Medical Group Limited
Lead Sponsor
T
Tokyo University
Collaborating Sponsor
AI-Summary
What this Trial Is About
Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-related death globally. Hepatocellular carcinoma represents about 90% of primary liver cancers and constitutes a major global health problem. The pattern of HCC occurrence shows a significant geographical imbalance, with the highest incidence rates in East Asia (more than 50% of the cases occurring in China). The aim of this study is to investigate the overall survival (OS) of patients diagnosed with unresectable hepatocellular carcinoma under real-world practice conditions in Asia Pacific region.
CONDITIONS
Official Title
The Overall Survival of Patients With Unresectable HCC in Real-life
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with a diagnosis of unresectable hepatocellular carcinoma
- Able to comprehend and provide written informed consent in accordance with institutional guidelines.
You will not qualify if you...
- Patients not willing to participate and/or give their written informed consent.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Beijing 302 Hospital
Beijing, China
Actively Recruiting
2
Humanity & Health Medical Group Limited
Hong Kong, Hong Kong
Actively Recruiting
3
Tokyo University
Tokyo, Japan
Actively Recruiting
Research Team
D
Danny Wang, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here